Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Novartis Acquires Sickle-Cell Drug Developer

Drug maker Novartis is acquiring Selexys Pharmaceuticals Corp., a developer of treatments for pain episodes associated with sickle cell disease, for $665 million. . . . → Read More: Novartis Acquires Sickle-Cell Drug Developer

Infusion-to-Oral Drug Delivery Company Acquired

A company with a technology for converting drugs given by intravenous infusion into pills and capsules was acquired Grünenthal Group, a provider of pain medications. . . . → Read More: Infusion-to-Oral Drug Delivery Company Acquired

Google Acquires Visual Interaction Tech Company

Google is acquiring Eyefluence Inc., developer of a technology that allows individuals to interact with computers, phones, and other devices using only their eyes. . . . → Read More: Google Acquires Visual Interaction Tech Company

Juno Acquires Biotech, Licenses Cell Sequencing Tech

Scanning electron micrograph of a human T-cell lymphocyte (National Institute of Allergy and Infectious Diseases, NIH)

11 January 2016. Juno Therapeutics is gaining single-cell sequencing technology for cancer immunotherapies through the buy-out of biotechnology company AbVitro Inc., and licensing part of that technology to pharmaceutical company Celgene Corp. The AbVitro acquisition is valued at . . . → Read More: Juno Acquires Biotech, Licenses Cell Sequencing Tech

Biotechs to Develop Antibody Therapies, Explore Merger

Downtown Vancouver (Magnus Larsson, Flickr)

8 January 2016. Two biotechnology companies in Vancouver agreed to collaborate on developing antibody treatments for cancer, with an option to merge their enterprises later on. The deal calls for Zymeworks Inc. to make an undisclosed equity investment in Kairos Therapeutics Inc. Zymeworks is also receiving $US 61.5 million . . . → Read More: Biotechs to Develop Antibody Therapies, Explore Merger

Rodin, Biogen Partner on Neurological Epigenetics

(Science360.gov)

6 January 2016. The biotechnology company Rodin Therapeutics is collaborating with Biogen, another biotech enterprise, in developing treatments based on epigenetics for neurological disorders. The agreement includes a $17.3 million equity investment in Rodin by Biogen and venture investor Atlas Venture, with an option for Biogen to acquire Rodin that provides further payments . . . → Read More: Rodin, Biogen Partner on Neurological Epigenetics

Diabetes Biotech Acquires GSK Spin-Off

ITCA 650 pump (Intacia Therapeutics)

24 September 2015. Intarcia Therapeutics, a developer of long-acting treatments for diabetes, is purchasing Phoundry Pharmaceuticals, a discoverer of engineered peptides for metabolic and other disorders. Phoundry — a spin-off company from GlaxoSmithKline in Research Triangle Park, North Carolina — is being acquired by Intarcia for an undisclosed amount . . . → Read More: Diabetes Biotech Acquires GSK Spin-Off

Spin-Off Formed to Develop Brain Disorder Therapies

(Arthur Toga, UCLA/NIH.gov)

16 September 2015. A new enterprise developing biologic therapies for disorders of the brain and nervous system is underway, spun-off from the acquisition in July 2015 of Naurex Inc. by the pharmaceutical company Allergan plc. The new company, Aptinyx Inc. in Evanston, Illinois will have many of the same team at . . . → Read More: Spin-Off Formed to Develop Brain Disorder Therapies

Intrexon Acquires Oxitec, Partners on Genetic Disorder

Diamondback moth (Olaf Leillinger, Wikimedia Commons)

10 August 2015. Intrexon Corp., a biotechnology company specializing in synthetic biology, is acquiring Oxitec Ltd., a designer of genetically modified insects to control the spread of disease-bearing and agricultural pests for $160 million. Intrexon is also partnering with Synthetic Biologics Inc. to develop therapies for phenylketonuria, a . . . → Read More: Intrexon Acquires Oxitec, Partners on Genetic Disorder

Allergan Acquires Depression Therapy Developer for $560M

(Lloyd Morgan, Flickr)

27 July 2015. Pharmaceutical maker Allergan plc is acquiring Naurex Inc., a designer of fast-acting therapies for depression and other neurological disorders, for $560 million. The deal covers Naurex’s products now in clinical trials, with the company’s technology platform and preclinical research spun-off into a new enterprise.

Naurex, a spin-off company . . . → Read More: Allergan Acquires Depression Therapy Developer for $560M